The article discusses the results of the phase 3 PERSEUS trial presented at ASH 2023. The trial showed that daratumumab combined with bortezomib, lenalidomide, and dexamethasone is more effective than the latter three drugs alone in treating newly diagnosed multiple myeloma patients. Chakra Chaulagain, MD, director of the myeloma and amyloidosis program at Cleveland Clinic Florida, stated that these findings are practice-changing and that the quadruplet therapy should be the standard treatment for newly diagnosed transplant-eligible multiple myeloma patients. Chaulagain reported receiving research funding from Alexion, Bristol Myers Squibb, and Janssen, and serving on the speaker’s bureau for Janssen and Sanofi.
Source link
PERSEUS trial results ‘practice-changing’ for newly diagnosed multiple myeloma
